C
Charles Lance Cowey
Researcher at Texas Oncology
Publications - 26
Citations - 3543
Charles Lance Cowey is an academic researcher from Texas Oncology. The author has contributed to research in topics: Nivolumab & Ipilimumab. The author has an hindex of 10, co-authored 26 publications receiving 2006 citations. Previous affiliations of Charles Lance Cowey include Baylor University Medical Center & Baylor University.
Papers
More filters
Journal ArticleDOI
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine
James Larkin,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,Piotr Rutkowski,Christopher D. Lao,Charles Lance Cowey,Dirk Schadendorf,John Wagstaff,R. Dummer,Pier Francesco Ferrucci,Michael Smylie,David W. Hogg,A. Hill,Ivan Marquez-Rodas,John B A G Haanen,Massimo Guidoboni,Michele Maio,Patrick Schöffski,M.S. Carlino,C. Lebbé,Grant A. McArthur,Paolo A. Ascierto,G.A. Daniels,Georgina V. Long,Lars Bastholt,Jasmine I. Rizzo,A. Balogh,Andriy Moshyk,F.S. Hodi,Jedd D. Wolchok +30 more
TL;DR: Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivoliumab alone than in those who received ipil optimumab alone, with no apparent loss of quality of life in the patients whoreceived regimens containing nivolinumab.
Journal ArticleDOI
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
F.S. Hodi,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,Piotr Rutkowski,Charles Lance Cowey,Christopher D. Lao,Dirk Schadendorf,John Wagstaff,Reinhard Dummer,Pier Francesco Ferrucci,Michael Smylie,Andrew F. Hill,David Hogg,Ivan Marquez-Rodas,Joel Jiang,Jasmine I. Rizzo,James Larkin,Jedd D. Wolchok,Jedd D. Wolchok +19 more
TL;DR: The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018.
Journal ArticleDOI
CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
Jedd D. Wolchok,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,Piotr Rutkowski,Christopher D. Lao,Charles Lance Cowey,Dirk Schadendorf,John Wagstaff,Reinhard Dummer,Pier Francesco Ferrucci,Michael Smylie,Marcus O. Butler,Andrew G. Hill,Ivan Marquez-Rodas,John B. A. G. Haanen,Tuba Bas,Wim van Dijck,James Larkin,F. Stephen Hodi +19 more
TL;DR: This 6.5-y analysis represents the longest follow-up from a phase 3 melanoma trial in the modern checkpoint inhibitor combination therapy and targeted therapy era and shows durable improved outcomes with NIVO + IPI and NivO vs IPI in pts with advanced melanoma.
Journal ArticleDOI
Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
Jeffrey S. Weber,M. Del Vecchio,Mario Mandalà,Helen Gogas,Ana Arance,Stéphane Dalle,Charles Lance Cowey,Michael Schenker,J.-J. Grob,V. Chiarion-Sileni,Ivan Marquez-Rodas,Marcus O. Butler,Michele Maio,Mark R. Middleton,T. Tang,Abdel Saci,V. de Pril,Maurice Lobo,J.M.G. Larkin,P.A. Ascierto +19 more
Journal ArticleDOI
Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).
Jeffrey S. Weber,Mario Mandalà,Michele Del Vecchio,Helen Gogas,Ana Arance,Charles Lance Cowey,Stéphane Dalle,Michael Schenker,Vanna Chiarion-Sileni,Ivan Marquez Rodas,Jean-Jacques Grob,Marcus O. Butler,Mark R. Middleton,Michele Maio,Victoria Atkinson,Reinhard Dummer,Veerle de Pril,Anila Qureshi,James Larkin,Paolo A. Ascierto +19 more
TL;DR: New efficacy results from CheckMate 238 are reported, with an additional 6 mo of follow-up, showing RFS continued to be significantly longer for NIVO vs IPI.